From September 3, 2018, five to ten projects are taking part in the trial run of the Business Acceleration Academy (BAA), a BioInnovation Institute flagship program. The program is designed to help early-stage projects move one step closer to bringing their research out of the lab and into the economy. The learnings from the trial run will help shape the first official BAA program in 2019.

The participating projects have already been chosen and are in pharma, medtech and industrial biotech. Before they join the BAA, they will already have established their technical proof of concept. The purpose of the BAA is then to uncover the commercial potential of their idea and develop the entrepreneurial competencies of the project teams.

“We have decided to work with a trial run to build the best possible program for our first open call for BAA. We have found a batch of very promising projects for the trial run, and we look forward to announcing the names of the projects soon”, says director Thomas Nagy.

The projects will go through a program tailor-made to their specific needs, and the Business Acceleration Academy is built around working sessions that cover topics such as go-to-market models, IP law and legal issues, idea pitching, and customer understanding.

“We want the teams to work hands-on with their projects and give them a feel of the mindset that is needed to be an entrepreneur. We have a strong competitive and commercial focus, and we are bringing in subject matter experts, start-up professionals and experienced mentors to support the projects”, says director Thomas Nagy.

The first open call for the Business Acceleration Academy is out. Read more.

Connect with us on LinkedIn to get more news on BII.

More news from BII
BII expands the team
First BII advisory board member announced